Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2018

Oct 17, 2018

32870_dirs_2018-10-17_382ac6de-2379-4aed-bccf-a00a7d782690.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2018-10-15

Reporting Person: Havey Adam (EVP, Business Operations)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-10-15 Common Stock M 6165 $25.62 Acquired 36079 Direct
2018-10-15 Common Stock S 6165 $60.1549 Disposed 29914 Direct
2018-10-15 Common Stock M 6165 $25.62 Acquired 36079 Direct
2018-10-15 Common Stock S 6165 $60.0293 Disposed 29914 Direct
2018-10-15 Common Stock S 661 $60.67 Disposed 29253 Direct
2018-10-16 Common Stock M 6165 $25.62 Acquired 35418 Direct
2018-10-16 Common Stock S 6165 $61.50 Disposed 29253 Direct
2018-10-16 Common Stock M 3840 $25.62 Acquired 33093 Direct
2018-10-16 Common Stock S 3840 $63.50 Disposed 29253 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-10-15 Stock Option (Right to Buy) $25.62 M 6165 Disposed 2021-03-10 Common Stock (6165) Direct
2018-10-15 Stock Option (Right to Buy) $25.62 M 6165 Disposed 2021-03-10 Common Stock (6165) Direct
2018-10-16 Stock Option (Right to Buy) $25.62 M 6165 Disposed 2021-03-10 Common Stock (6165) Direct
2018-10-16 Stock Option (Right to Buy) $25.62 M 3840 Disposed 2021-03-10 Common Stock (3840) Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.31 to $60.67, inclusive.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.50 to $60.67, inclusive.

F4: Consists of an option granted under the company's stock incentive plan as amended and restated.

F5: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant.